Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression

Current Molecular Medicine

Volumn 13, Issue 4, 2013, Pages 555-571

  Ruscica, M ^a   Arvigo, M ^b   Steffani, L ^a   Ferone, D ^b   Magni, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Angiogenesis in cancer; Cancer cell proliferation; Metastatization; Somatostatin; Somatostatin analogs in cancer; Somatostatin receptors in cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DIMER; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GROWTH HORMONE; MU OPIATE RECEPTOR; PROTEIN P53; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL DIVISION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DIMERIZATION; ENZYME REPRESSION; HORMONE RELEASE; HUMAN; METASTASIS; MODULATION; NONHUMAN; PROTEIN EXPRESSION; SECRETION (PROCESS);

ANIMALS; CELL PROLIFERATION; DIMERIZATION; DISEASE PROGRESSION; HUMANS; NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84876736523     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313040008     Document Type: Article

References (190)

1. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.
2. Zatelli MC. Antiproliferative effects of somatostatin analogs in endocrine tumours. F1000 Med Rep 2009; 1: 40.
3. Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncol 2011; 7: 895-913.
4. Righi L, Volante M, Tavaglione V, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol 2010; 21: 548-555.
5. Ioannou M, Papagelopoulos PJ, Papanastassiou I, Iakovidou I, Kottakis S, Demertzis N. Detection of somatostatin receptors in human osteosarcoma. World J Surg Oncol 2008; 6: 99.
6. Klagge A, Krause K, Schierle K, Steinert F, Dralle H, Fuhrer D. Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res 2010; 42: 237-40.
7. Schaer JC, Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997; 70: 530-7.
8. Volante M, Rosas R, Allia E, et al. Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol 2008; 286: 219-29.
9. Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci 1994; 55: 1797-806.
10. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 2000; 85: 3882-91.
11. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968; 83: 783-90.
12. Esch F, Bohlen P, Ling N, Benoit R, Brazeau P, Guillemin R. Primary structure of ovine hypothalamic somatostatin-28 and somatostatin-25. Proc Natl Acad Sci USA 1980; 77: 6827-31.
13. Polak JM, Pearse AG, Grimelius L, Bloom SR. Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. Lancet 1975; 1: 1220-2.
14. Alumets J, Sundler F, Hakanson R. Distribution, ontogeny and ultrastructure of somatostatin immunoreactive cells in the pancreas and gut. Cell Tissue Res 1977; 185: 465-79.
15. Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495-1501.
16. Reichlin S. Somatostatin (second of two parts). N Engl J Med 1983; 309: 1556-1563.
17. Helboe L, Moller M. Localization of somatostatin receptors at the light and electron microscopial level by using antibodies raised against fusion proteins. Prog Histochem Cytochem 2000; 35: 3-64.
18. Lewin MJ. The somatostatin receptor in the GI tract. Annu Rev Physiol 1992; 54: 455-68.
19. Epelbaum J, Dournaud P, Fodor M, Viollet C. The neurobiology of somatostatin. Crit Rev Neurobiol 1994; 8: 25-44.
20. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 2001; 86: 2976-81.
21. Ferone D, Pivonello R, Van Hagen PM, et al. Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab 2002; 283: E1056-1066.
22. Ferrante E, Pellegrini C, Bondioni S, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006; 13: 955-962.
23. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008; 13: 822-840.
24. Ruscica M, Arvigo M, Gatto F, et al. Regulation of prostate cancer cell proliferation by somatostatin receptor activation. Mol Cell Endocrinol 2010; 315: 254-262.
25. Pradayrol L, Jornvall H, Mutt V, Ribet A. N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Lett 1980; 109: 55-58.
26. Schally AV, Huang WY, Chang RC, et al. Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus. Proc Natl Acad Sci USA 1980; 77: 4489-4493.
27. Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine 2003; 20: 255-264.
28. Brakch N, Lazar N, Panchal M, et al. The somatostatin-28(1-12)-NPAMAP sequence: an essential helical-promoting motif governing prosomatostatin processing at mono- and dibasic sites. Biochemistry 2002; 41: 1630-1639.
29. Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion 2000; 62 Suppl 1: 27-32.
30. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-98.
31. Baumeister H, Meyerhof W. Gene regulation of somatostatin receptors in rats. J Physiol Paris 2000; 94: 167-177.
32. Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W. Regulation and function of somatostatin receptors. J Neurochem 2004; 89: 1057-1091.
33. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 1992; 89: 251-255.
34. Corness JD, Demchyshyn LL, Seeman P, et al. A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett 1993; 321: 279-284.
35. Rohrer L, Raulf F, Bruns C, Buettner R, Hofstaedter F, Schule R. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 1993; 90: 4196-4200.
36. Panetta R, Greenwood MT, Warszynska A, et al. Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol 1994; 45: 417-427.
37. Horn F, Weare J, Beukers MW, et al. GPCRDB: an information system for G protein-coupled receptors. Nucleic Acids Res 1998; 26: 275-279.
38. Horn F, Bettler E, Oliveira L, Campagne F, Cohen FE, Vriend G. GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res 2003; 31: 294-297.
39. Vroling B, Sanders M, Baakman C, et al. GPCRDB: information system for G protein-coupled receptors. Nucleic Acids Res 2011; 39: D309-319.
40. Davies MN, Secker A, Halling-Brown M, et al. GPCRTree: online hierarchical classification of GPCR function. BMC Res Notes 2008; 1: 67.
41. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular Mechanism of b-Arrestin-Biased Agonism at Seven-Transmembrane Receptors. Annu Rev Pharmacol Toxicol 2012; 52: 179-197.
42. Agnati LF, Ferre S, Lluis C, Franco R, Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 2003; 55: 509-550.
43. Kreienkamp HJ, Soltau M, Richter D, Bockers T. Interaction of G-protein-coupled receptors with synaptic scaffolding proteins. Biochem Soc Trans 2002; 30: 464-468.
44. Duran-Prado M, Gahete MD, Martinez-Fuentes AJ, et al. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 2009; 94: 2634-2643.
45. Cordoba-Chacon J, Gahete MD, Duran-Prado M, et al. Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol Life Sci 2010; 67: 1147-1163.
46. Duran-Prado M, Saveanu A, Luque RM, et al. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab 2010; 95: 2497-2502.
47. Duran-Prado M, Gahete MD, Hergueta-Redondo M, et al. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene 2012; 31: 2049-2061.
48. Cordoba-Chacon J, Gahete MD, Duran-Prado M, Luque RM, Castano JP. Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology. Ann N Y Acad Sci 2011; 1220: 6-15.
49. Johansson M, McKay JD, Wiklund F, et al. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18: 1644-150.
50. Canzian F, McKay JD, Cleveland RJ, et al. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomarkers Prev 2005; 14: 2316-2325.
51. Li D, Tanaka M, Brunicardi FC, Fisher WE, Gibbs RA, Gingras MC. Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival. Cancer 2011; 117: 2863-2872.
52. Ciganoka D, Balcere I, Kapa I, et al. Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly. Eur J Endocrinol 2011; 165: 517-525.
53. Sun LC, Coy DH. Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv 2011; 8: 2-10.
54. Sestini R, Orlando C, Peri A, et al. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clin Cancer Res 1996; 2: 1757-1765.
55. Slaby O, Sachlova M, Bednarikova M, et al. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs. Cancer Biother Radiopharm 2010; 25: 237-243.
56. Gatto F, Barbieri F, Castelletti L, et al. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary 2011; 14: 141-7.
57. Gatto F, Barbieri F, Gatti M, et al. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clin Endocrinol (Oxf) 2012; 76: 407-14.
58. Lewis I, Albert R, Kneuer R, et al. Medicinal chemistry of somatostatin analogs leading to the DTPA and DOTA conjugates of the multi-receptor-ligand SOM230. J Endocrinol Invest 2005; 28: 15-20.
59. Marbach P, Bauer W, Briner U, Dopfner W, Petcher T, Pless J. Structure-function relationships of somatostatin analogs. Horm Res 1988; 29: 54-58.
60. Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998; 282: 737-740.
61. Marks N, Stern F. Inactivation of somatostatin (GH-RIH) and its an analogs by crude and partially purified rat brain extracts. FEBS Lett 1975; 55: 220-224.
62. Pless J. The history of somatostatin analogs. J Endocrinol Invest 2005; 28: 1-4.
63. Pawlikowski M, Melen-Mucha G. Somatostatin analogs -from new molecules to new applications. Curr Opin Pharmacol 2004; 4: 608-613.
64. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006; 355: 2558-2573.
65. Veber DF, Freidlinger RM, Perlow DS, et al. A potent cyclic hexapeptide analogue of somatostatin. Nature 1981; 292: 55-58.
66. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133-1140.
67. Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 2009; 25: 2989-2999.
68. Hannon JP, Nunn C, Stolz B, et al. Drug design at peptide receptors: somatostatin receptor ligands. J Mol Neurosci 2002; 18: 15-27.
69. De Martino MC, Hofland LJ, Lamberts SW. Somatostatin and somatostatin receptors: from basic concepts to clinical applications. Prog Brain Res 2010; 182: 255-280.
70. Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 1997; 70: 471-479.
71. Culler MD. Evolving concepts in the quest for advanced therapeutic analogues of somatostatin. Dig Liver Dis 2004; 36 Suppl 1: S17-25.
72. Jaquet P, Saveanu A, Gunz G, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000; 85: 781-792.
73. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008; 286: 69-74.
74. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146: 707-716.
75. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366: 914-924.
76. Oncology TPoN. A Pipeline that Spans All Phases. Available at:http://www.novartisoncology.com/research-innovation/pipeline.jsp. [accessed 2012].
77. Colao A, Bronstein M, Freda PU, et al. Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study. 2012 Joint 15th International Congress of Endocrinology and 14th European Congress of Endocrinology; 7 May 2012; Florence: BioScientifica; 2012.
78. Reubi JC, Eisenwiener KP, Rink H, Waser B, Macke HR. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002; 456: 45-49.
79. Jaquet P, Gunz G, Saveanu A, et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005; 28: 21-27.
80. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006; 83: 258-263.
81. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288: 154-157.
82. Prinster SC, Hague C, Hall RA. Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol Rev 2005; 57: 289-298.
83. Flogstad AK, Halse J, Grass P, et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994; 79: 461-465.
84. Li JK, Chow CC, Yeung VT, et al. Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide. Aust N Z J Med 2000; 30: 457-461.
85. Saveanu A, Lavaque E, Gunz G, et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002; 87: 5545-5552.
86. Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86: 140-145.
87. Zatelli MC, Piccin D, Tagliati F, et al. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 2003; 88: 2797-802.
88. Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Oberg K, Janson ET. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells. Med Oncol 2004; 21: 285-295.
89. Zatelli MC, Piccin D, Bottoni A, et al. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 2004; 89: 5181-5188.
90. Zatelli MC, Maffei P, Piccin D, et al. Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J Clin Endocrinol Metab 2005; 90: 2104-2109.
91. Bocci G, Culler MD, Fioravanti A, et al. In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. Eur J Clin Invest 2007; 37: 700-708.
92. Ludvigsen E, Stridsberg M, Taylor JE, et al. Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues. Regul Pept 2007; 138: 1-9.
93. Arvigo M, Gatto F, Ruscica M, et al. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. J Endocrinol 2010; 207: 309-317.
94. Reubi JC, Schaer JC, Wenger S, et al. SST3-selective potent peptidic somatostatin receptor antagonists. Proc Natl Acad Sci USA 2000; 97: 13973-13978.
95. Ramon R, Martin-Gago P, Verdaguer X, et al. SSTR1- and SSTR3-Selective Somatostatin Analogues. Chembiochem 2011; 12: 625-632.
96. Kumar U. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis. Neuroscience 2005; 134: 525-538.
97. Crider AM, Witt KA. Somatostatin sst4 ligands: chemistry and pharmacology. Mini Rev Med Chem 2007; 7: 213-220.
98. Elekes K, Helyes Z, Kereskai L, et al. Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperactivity in the mouse. Eur J Pharmacol 2008; 578: 313-322.
99. Kuriyama I, Miyazaki A, Tsuda Y, et al. Inhibitory effect of somatostatin Peptide analogues on DNA polymerase activity and human cancer cell proliferation. Anticancer Res 2010; 30: 4841-4849.
100. Afargan M, Janson ET, Gelerman G, et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 2001; 142: 477-486.
101. Shimon I, Rubinek T, Hadani M, Alhadef N. PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. J Endocrinol Invest 2004; 27: 721-727.
102. Jean-Alphonse F, Hanyaloglu AC. Regulation of GPCR signal networks via membrane trafficking. Mol Cell Endocrinol 2011; 331: 205-214.
103. Salahpour A, Barak LS. Visualizing receptor endocytosis and trafficking. Methods Mol Biol 2011; 756: 311-323.
104. van Koppen CJ, Jakobs KH. Arrestin-independent internalization of G protein-coupled receptors. Mol Pharmacol 2004; 66: 365-367.
105. Jacobs S, Schulz S. Intracellular trafficking of somatostatin receptors. Mol Cell Endocrinol 2008; 286: 58-62.
106. Liu Q, Schonbrunn A. Agonist-induced phosphorylation of somatostatin receptor subtype 1 (sst1). Relationship to desensitization and internalization. J Biol Chem 2001; 276: 3709-3717.
107. Roosterman D, Kreuzer OJ, Brune N, et al. Agonist-induced endocytosis of rat somatostatin receptor 1. Endocrinology 2007; 148: 1050-1058.
108. Plockinger U, Albrecht S, Mawrin C, et al. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 2008; 93: 1203-12010.
109. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009; 50: 936-941.
110. Reubi JC, Waser B, Cescato R, Gloor B, Stettler C, Christ E. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab 2010; 95: 2343-2350.
111. Cescato R, Schulz S, Waser B, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006; 47: 502-511.
112. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009; 94: 654-6561.
113. Kreuzer OJ, Krisch B, Dery O, Bunnett NW, Meyerhof W. Agonist-mediated endocytosis of rat somatostatin receptor subtype 3 involves beta-arrestin and clathrin coated vesicles. J Neuroendocrinol 2001; 13: 279-287.
114. Tower-Gilchrist C, Lee E, Sztul E. Endosomal trafficking of the G protein-coupled receptor somatostatin receptor 3. Biochem Biophys Res Commun 2011; 413: 555-560.
115. Smalley KS, Feniuk W, Humphrey PP. Differential agonist activity of somatostatin and L-362855 at human recombinant sst4 receptors. Br J Pharmacol 1998; 125: 833-841.
116. Smalley KS, Koenig JA, Feniuk W, Humphrey PP. Ligand internalization and recycling by human recombinant somatostatin type 4 (h sst(4)) receptors expressed in CHO-K1 cells. Br J Pharmacol 2001; 132: 1102-1110.
117. Stroh T, Jackson AC, Dal Farra C, Schonbrunn A, Vincent JP, Beaudet A. Receptor-mediated internalization of somatostatin in rat cortical and hippocampal neurons. Synapse 2000; 38: 177-186.
118. Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996; 137: 4046-4049.
119. Koenig JA, Edwardson JM, Humphrey PP. Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization. Br J Pharmacol 1997; 120: 52-59.
120. Peverelli E, Mantovani G, Calebiro D, et al. The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation. Mol Endocrinol 2008; 22: 676-688.
121. Hukovic N, Panetta R, Kumar U, Rocheville M, Patel YC. The cytoplasmic tail of the human somatostatin receptor type 5 is crucial for interaction with adenylyl cyclase and in mediating desensitization and internalization. J Biol Chem 1998; 273: 21416-21422.
122. Grant M, Patel RC, Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem 2004; 279: 38636-38643.
123. Duran-Prado M, Malagon MM, Gracia-Navarro F, Castano JP. Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol Cell Endocrinol 2008; 286: 63-68.
124. Csaba Z, Peineau S, Dournaud P. Molecular mechanisms of somatostatin receptor trafficking. J Mol Endocrinol 2012; 48: R1-12.
125. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 2007; 19: 2304-2316.
126. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000; 275: 7862-7869.
127. Patel RC, Kumar U, Lamb DC, et al. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA 2002; 99: 3294-3299.
128. Pfeiffer M, Koch T, Schroder H, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 2001; 276: 14027-14036.
129. War SA, Somvanshi RK, Kumar U. Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. Biochim Biophys Acta 2011; 1813: 390-402.
130. Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 2008; 22: 2278-2292.
131. Sharif N, Gendron L, Wowchuk J, et al. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 2007; 148: 2095-2105.
132. Grant M, Collier B, Kumar U. Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J Biol Chem 2004; 279: 36179-36183.
133. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Hollt V, Schulz S. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 2004; 279: 21374-21382.
134. Duran-Prado M, Bucharles C, Gonzalez BJ, et al. Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization. Endocrinology 2007; 148: 411-421.
135. Grant M, Kumar U. The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul Pept 2010; 159: 3-8.
136. Somvanshi RK, Billova S, Kharmate G, Rajput PS, Kumar U. C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell Signal 2009; 21: 1396-1414.
137. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 2002; 277: 19762-19772.
138. Ferone D, Gatto F, Arvigo M, et al. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 2009; 42: 361-370.
139. Hofland LJ, Feelders RA, de Herder WW, Lamberts SW. Pituitary tumours: the sst/D2 receptors as molecular targets. Mol Cell Endocrinol 2010; 326: 89-98.
140. Ren SG, Kim S, Taylor J, et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003; 88: 5414-5421.
141. Kidd M, Drozdov I, Joseph R, Pfragner R, Culler M, Modlin I. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008; 113: 690-700.
142. Culler MD. Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors. Horm Metab Res 2011; 43: 854-857.
143. Schulz S, Schreff M, Schmidt H, Handel M, Przewlocki R, Hollt V. Immunocytochemical localization of somatostatin receptor sst2A in the rat spinal cord and dorsal root ganglia. Eur J Neurosci 1998; 10: 3700-3708.
144. Bereiter DA. Morphine and somatostatin analogue reduce c-fos expression in trigeminal subnucleus caudalis produced by corneal stimulation in the rat. Neuroscience 1997; 77: 863-874.
145. Bell JR, Young MR, Masterman SC, Morris A, Mattick RP, Bammer G. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust 1999; 171: 26-30.
146. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Mol Cell Endocrinol 2008; 286: 230-237.
147. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006; 17: 1733-1742.
148. Steffani L, Passafaro L, Ferone D, Magni P, Ruscica M. Somatostatin (SS), SS receptors and SS analog treatment in tumorigenesis. Atlas of Genetics and Cytogenetics in Oncology andHaematology 2011; [http://AtlasGeneticsOncology.org/Deep/SomatostatinID2009 4.html].
149. Theodoropoulou M, Zhang J, Laupheimer S, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006; 66: 1576-1582.
150. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
151. Lahlou H, Saint-Laurent N, Esteve JP, et al. SST2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003; 278: 39356-39371.
152. Arena S, Pattarozzi A, Massa A, et al. An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta. Mol Endocrinol 2007; 21: 229-246.
153. Hubina E, Ruscica M, Nanzer AM, et al. Novel molecular aspects of pituitary adenomas. J Endocrinol Invest 2005; 28: 87-92.
154. Hubina E, Nanzer AM, Hanson MR, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006; 155: 371-379.
155. Barbieri F, Pattarozzi A, Gatti M, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab 2009; 297: E1078-1088.
156. Barbieri F, Pattarozzi A, Gatti M, et al. Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2. Endocrinology 2008; 149: 4736-4746.
157. Zatelli MC, Tagliati F, Taylor JE, Piccin D, Culler MD, degli Uberti EC. Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm Metab Res 2002; 34: 229-233.
158. Zatelli MC, Piccin D, Tagliati F, et al. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab 2006; 91: 2218-2224.
159. Ning S, Knox SJ, Harsh GR, Culler MD, Katznelson L. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Endocr Relat Cancer 2009; 16: 1045-1055.
160. Ferjoux G, Bousquet C, Cordelier P, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 2000; 94: 205-210.
161. Gruszka A, Kunert-Radek J, Pawlikowski M. The effect of octreotide and bromocriptine on expression of a pro-apoptotic Bax protein in rat prolactinoma. Folia Histochem Cytobiol 2004; 42: 35-39.
162. Luciani P, Gelmini S, Ferrante E, et al. Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2005; 90: 6156-6161.
163. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10: 1688-1696.
164. Batista DL, Zhang X, Gejman R, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006; 91: 4482-8.
165. Lattuada D, Casnici C, Crotta K, et al. Inhibitory effect of pasireotide and octreotide on lymphocyte activation. J Neuroimmunol 2007; 182: 153-159.
166. Fedele M, De Martino I, Pivonello R, et al. SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin Cancer Res 2007; 13: 2738-2744.
167. Martinez-Alonso M, Llecha N, Mayorga ME, et al. Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation. J Int Med Res 2009; 37: 1813-18122.
168. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
169. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
170. Lyons J, 3rd, Anthony CT, Woltering EA. The role of angiogenesis in neuroendocrine tumors. Endocrinol Metab Clin North Am 2010; 39: 839-852.
171. Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. J Surg Oncol 2011; 103: 468-474.
172. Woltering EA, Watson JC, Alperin-Lea RC, et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 1997; 15: 77-86.
173. Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous novel [corrected] regulators of angiogenesis. Pharmacol Rev 2007; 59: 185-205.
174. Garcia de la Torre N, Wass JA, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 2002; 57: 425-41.
175. Albini A, Florio T, Giunciuglio D, et al. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J 1999; 13: 647-55.
176. Polverini PJ. Role of the macrophage in angiogenesis-dependent diseases. EXS 1997; 79: 11-28.
177. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-45.
178. Gulec SA, Drouant GJ, Fuselier J, et al. Antitumor and antiangiogenic effects of somatostatin receptor-targeted in situ radiation with (111)In-DTPA-JIC 2DL. J Surg Res 2001; 97: 131-7.
179. Florio T, Morini M, Villa V, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003; 144: 1574-84.
180. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 2006; (96): 223-268.
181. Terranova VP, Hic S, Diflorio RM, Lyall RM. Tumor cell metastasis. Crit Rev Oncol Hematol 1986; 5: 87-114.
182. Sun LC, Luo J, Mackey LV, Fuselier JA, Coy DH. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Lett 2007; 246: 157-166.
183. Feng Y, Huang T, Gao J, Chang Q, Qin R. Inhibition of metastatic progression of SSTR2 gene transfection mediated by adenovirus in human pancreatic carcinoma cells. J Huazhong Univ Sci Technolog Med Sci 2006; 26: 68-71.
184. Pola S, Cattaneo MG, Vicentini LM. Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity. J Biol Chem 2003; 278: 40601-40606.
185. Cattaneo MG, Gentilini D, Vicentini LM. Deregulated human glioma cell motility: inhibitory effect of somatostatin. Mol Cell Endocrinol 2006; 256: 34-9.
186. Annunziata M, Luque RM, Duran-Prado M, et al. Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility. Hum Reprod 2012; 27: 2117-2129.
187. Lahlou H, Fanjul M, Pradayrol L, Susini C, Pyronnet S. Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells. Mol Cell Biol 2005; 25: 4034-4045.
188. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999; 141: 1-14.
189. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept:100 years of progress. Nat Rev Cancer 2008; 8: 473-480.
190. Ruscica M, Dozio E, Motta M, Magni P. Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer. Peptides 2007; 28: 426-434.